{"id":"https://openalex.org/W3203034103","doi":"https://doi.org/10.1136/bmjdrc-2021-002137","title":"Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies","display_name":"Comparison of a ready-to-use liquid glucagon injection administered by autoinjector to glucagon emergency kit for the symptomatic relief of severe hypoglycemia: two randomized crossover non-inferiority studies","alternate_titles":[],"publication_year":2021,"publication_date":"2021-10-01","ids":{"openalex":"https://openalex.org/W3203034103","doi":"https://doi.org/10.1136/bmjdrc-2021-002137","mag":"3203034103","pmid":"https://pubmed.ncbi.nlm.nih.gov/34620618","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/8499286"},"language":"en","primary_location":{"id":"doi:10.1136/bmjdrc-2021-002137","doi":"https://doi.org/10.1136/bmjdrc-2021-002137","is_oa":true,"landing_page_url":"https://doi.org/10.1136/bmjdrc-2021-002137","pdf_url":"https://drc.bmj.com/content/bmjdrc/9/1/e002137.full.pdf","source":{"id":"https://openalex.org/S2764997855","display_name":"BMJ Open Diabetes Research & Care","issn_l":"2052-4897","issn":["2052-4897"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Diabetes Research &amp; Care","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W3203034103"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://drc.bmj.com/content/bmjdrc/9/1/e002137.full.pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103817327","display_name":"Mark P. Christiansen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210134670","display_name":"Diablo Clinical Research","ror":"https://ror.org/03j4y6x14","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210134670"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mark P Christiansen","raw_affiliation_strings":["Diablo Clinical Research, Walnut Creek, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Diablo Clinical Research, Walnut Creek, California, USA","institution_ids":["https://openalex.org/I4210134670"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054382546","display_name":"Martin J. Cummins","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086595","display_name":"Xeris Pharmaceuticals (United States)","ror":"https://ror.org/001t4p955","country_code":"US","type":"company","lineage":["https://openalex.org/I4210086595"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin Cummins","raw_affiliation_strings":["Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA","institution_ids":["https://openalex.org/I4210086595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111425447","display_name":"Steven J. Prestrelski","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210086595","display_name":"Xeris Pharmaceuticals (United States)","ror":"https://ror.org/001t4p955","country_code":"US","type":"company","lineage":["https://openalex.org/I4210086595"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Steven Prestrelski","raw_affiliation_strings":["Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA","institution_ids":["https://openalex.org/I4210086595"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064701617","display_name":"Nicole Close","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicole C Close","raw_affiliation_strings":["EmpiriStat Inc, Kitty Hawk, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"EmpiriStat Inc, Kitty Hawk, North Carolina, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005642172","display_name":"Anh Phuong Nguyen","orcid":"https://orcid.org/0000-0003-3483-2668","observed_orcids":["https://orcid.org/0000-0003-3483-2668"]},"institutions":[{"id":"https://openalex.org/I4210086595","display_name":"Xeris Pharmaceuticals (United States)","ror":"https://ror.org/001t4p955","country_code":"US","type":"company","lineage":["https://openalex.org/I4210086595"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Anh Nguyen","raw_affiliation_strings":["Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA","institution_ids":["https://openalex.org/I4210086595"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5010087451","display_name":"Khaled Junaidi","orcid":"https://orcid.org/0000-0003-0581-5412","observed_orcids":["https://orcid.org/0000-0003-0581-5412"]},"institutions":[{"id":"https://openalex.org/I4210086595","display_name":"Xeris Pharmaceuticals (United States)","ror":"https://ror.org/001t4p955","country_code":"US","type":"company","lineage":["https://openalex.org/I4210086595"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Khaled Junaidi","raw_affiliation_strings":["Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA"],"raw_orcid":"https://orcid.org/0000-0003-0581-5412","affiliations":[{"raw_affiliation_string":"Clinical Development, Xeris Pharmaceuticals Inc, Chicago, Illinois, USA","institution_ids":["https://openalex.org/I4210086595"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5010087451"],"corresponding_institution_ids":["https://openalex.org/I4210086595"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":{"value":3000,"currency":"USD","value_usd":3000},"fwci":2.9052,"has_fulltext":true,"cited_by_count":24,"citation_normalized_percentile":{"value":0.91662592,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"9","issue":"1","first_page":"e002137","last_page":"e002137"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10508","display_name":"Patient Safety and Medication Errors","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/glucagon","display_name":"glucagon","score":0.7929999828338623},{"id":"https://openalex.org/keywords/severe-hypoglycemia","display_name":"severe hypoglycemia","score":0.9490000009536743},{"id":"https://openalex.org/keywords/type-1-diabetes","display_name":"type 1 diabetes","score":0.9409999847412109},{"id":"https://openalex.org/keywords/insulin-induced-hypoglycemia","display_name":"insulin-induced hypoglycemia","score":0.9169999957084656},{"id":"https://openalex.org/keywords/neuroglycopenic-symptoms","display_name":"neuroglycopenic symptoms","score":0.8140000104904175},{"id":"https://openalex.org/keywords/non-inferiority","display_name":"non-inferiority","score":0.8180000185966492},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.7490000128746033},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.43700000643730164}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.933659553527832},{"id":"https://openalex.org/C2778563252","wikidata":"https://www.wikidata.org/wiki/Q170617","display_name":"Glucagon","level":3,"score":0.746913492679596},{"id":"https://openalex.org/C2780668416","wikidata":"https://www.wikidata.org/wiki/Q202758","display_name":"Hypoglycemia","level":3,"score":0.7282997369766235},{"id":"https://openalex.org/C87813604","wikidata":"https://www.wikidata.org/wiki/Q1242899","display_name":"Crossover study","level":4,"score":0.6213955283164978},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.5258738994598389},{"id":"https://openalex.org/C177713679","wikidata":"https://www.wikidata.org/wiki/Q679690","display_name":"Intensive care medicine","level":1,"score":0.38798174262046814},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.37000930309295654},{"id":"https://openalex.org/C194828623","wikidata":"https://www.wikidata.org/wiki/Q2861470","display_name":"Emergency medicine","level":1,"score":0.35014206171035767},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.23414543271064758},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.2146536409854889},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.20039963722229004},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.18116497993469238},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005934","descriptor_name":"Glucagon","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000139","qualifier_name":"chemically induced","is_major_topic":true},{"descriptor_ui":"D007003","descriptor_name":"Hypoglycemia","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007328","descriptor_name":"Insulin","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018592","descriptor_name":"Cross-Over Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1136/bmjdrc-2021-002137","doi":"https://doi.org/10.1136/bmjdrc-2021-002137","is_oa":true,"landing_page_url":"https://doi.org/10.1136/bmjdrc-2021-002137","pdf_url":"https://drc.bmj.com/content/bmjdrc/9/1/e002137.full.pdf","source":{"id":"https://openalex.org/S2764997855","display_name":"BMJ Open Diabetes Research & Care","issn_l":"2052-4897","issn":["2052-4897"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Diabetes Research &amp; Care","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:8499286","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8499286/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Diabetes Res Care","raw_type":"Text"},{"id":"pmid:34620618","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/34620618","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ open diabetes research & care","raw_type":"Clinical Trial, Phase III"},{"id":"pmh:oai:doaj.org/article:e17d099bf97645298d125e610969a48d","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/e17d099bf97645298d125e610969a48d","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"BMJ Open Diabetes Research & Care, Vol 9, Iss 1 (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1136/bmjdrc-2021-002137","doi":"https://doi.org/10.1136/bmjdrc-2021-002137","is_oa":true,"landing_page_url":"https://doi.org/10.1136/bmjdrc-2021-002137","pdf_url":"https://drc.bmj.com/content/bmjdrc/9/1/e002137.full.pdf","source":{"id":"https://openalex.org/S2764997855","display_name":"BMJ Open Diabetes Research & Care","issn_l":"2052-4897","issn":["2052-4897"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-100","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310319945","host_organization_name":"BMJ","host_organization_lineage":["https://openalex.org/P4310319945"],"host_organization_lineage_names":["BMJ"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"BMJ Open Diabetes Research &amp; Care","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307758","display_name":"Eli Lilly and Company","ror":"https://ror.org/01qat3289"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320316051","display_name":"Dexcom","ror":"https://ror.org/03ra42c27"},{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"},{"id":"https://openalex.org/F4320333256","display_name":"Abbott Diabetes Care","ror":"https://ror.org/03vb88585"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3203034103.pdf","grobid_xml":"https://content.openalex.org/works/W3203034103.grobid-xml"},"referenced_works_count":21,"referenced_works":["https://openalex.org/W1802476941","https://openalex.org/W2018647362","https://openalex.org/W2059158127","https://openalex.org/W2075361652","https://openalex.org/W2107648636","https://openalex.org/W2126515546","https://openalex.org/W2126962035","https://openalex.org/W2158756137","https://openalex.org/W2213182784","https://openalex.org/W2276228986","https://openalex.org/W2284954176","https://openalex.org/W2311902495","https://openalex.org/W2444446211","https://openalex.org/W2582743722","https://openalex.org/W2618448180","https://openalex.org/W2624087031","https://openalex.org/W2781395153","https://openalex.org/W2949402067","https://openalex.org/W2972241431","https://openalex.org/W3015267091","https://openalex.org/W4236126199"],"related_works":["https://openalex.org/W2809400619","https://openalex.org/W2809585414","https://openalex.org/W2948583814","https://openalex.org/W3216078065","https://openalex.org/W2949402067","https://openalex.org/W2809326658","https://openalex.org/W4286310442","https://openalex.org/W3174852078","https://openalex.org/W3177183651","https://openalex.org/W2948531902"],"abstract_inverted_index":{"INTRODUCTION:":[0],"To":[1],"prevent":[2],"medical":[3],"sequelae":[4],"of":[5,39,69,88,106,114,156,211],"severe":[6,40,79,244],"hypoglycemic":[7],"emergencies,":[8],"prompt":[9],"and":[10,180,198,239,246,257],"reliable":[11],"rescue":[12,37,241],"intervention":[13],"is":[14,235,247],"critically":[15],"important.":[16],"A":[17,222],"ready-to-use,":[18],"liquid":[19],"stable":[20],"glucagon,":[21,157],"administered":[22],"subcutaneously":[23],"by":[24],"glucagon":[25,72],"autoinjector":[26],"(GAI),":[27],"Gvoke":[28],"HypoPen":[29],"(glucagon":[30],"injection;":[31],"Xeris":[32],"Pharmaceuticals),":[33],"was":[34,82,128,135,175,216,225],"evaluated":[35,83],"for":[36,76,139,178,183,191,201,243],"treatment":[38,125,212,242],"hypoglycemia.":[41,80],"RESEARCH":[42],"DESIGN":[43],"AND":[44],"METHODS:":[45],"Two":[46],"phase":[47],"III,":[48],"randomized,":[49],"controlled,":[50],"blinded,":[51],"non-inferiority":[52],"crossover":[53],"studies":[54],"were":[55],"conducted":[56],"in":[57,218],"161":[58],"adults":[59],"with":[60,126,133,229],"type":[61],"1":[62,66],"diabetes":[63],"to":[64,91,130,137,161,227,251],"compare":[65],"mg":[67],"doses":[68],"GAI":[70,127,134,179,202,224,234],"versus":[71,205],"emergency":[73],"kit":[74],"(GEK)":[75],"treating":[77],"insulin-induced":[78],"Efficacy":[81],"as":[84],"either":[85],"a":[86,103,140,230,248],"return":[87],"plasma":[89,119,141,163],"glucose":[90,105,120,142,164],">70":[92,143,165],"mg/dL":[93,99,108,144,166,172],"(3.9":[94,145,167],"mmol/L)":[95,101,146,168,174],"or":[96,147,169],"increase":[97,170],"\u226520":[98,171],"(1.1":[100,173],"from":[102],"baseline":[104],"<50":[107],"(2.9":[109],"mmol/L),":[110],"within":[111,122,151],"30":[112,123,152],"min":[113,177,182],"dosing.":[115],"RESULTS:":[116],"For":[117],"successful":[118],"recovery":[121],"min,":[124],"non-inferior":[129,136,226],"GEK.":[131,184,252],"Treatment":[132],"GEK":[138,206],"neuroglycopenic":[148],"symptom":[149],"relief":[150],"min.":[153],"From":[154],"administration":[155,199],"the":[158,192],"mean":[159,186],"time":[160,187,200],"achieve":[162],"13.8\u00b15.6":[176],"10.0\u00b13.6":[181],"This":[185],"does":[188],"not":[189],"account":[190],"significantly":[193],"shorter":[194],"(p<0.0001)":[195],"drug":[196],"preparation":[197],"(27.3\u00b119.7":[203],"s)":[204],"(97.2\u00b145.1":[207],"s).":[208],"The":[209],"incidence":[210],"emergent":[213],"adverse":[214],"events":[215],"comparable":[217],"both":[219],"groups.":[220],"CONCLUSIONS:":[221],"ready-to-use":[223],"GEK,":[228],"similar":[231],"tolerability":[232],"profile.":[233],"an":[236],"effective,":[237],"safe,":[238],"well-tolerated":[240],"hypoglycemia":[245],"viable":[249],"alternative":[250],"TRIAL":[253],"REGISTRATION":[254],"NUMBERS:":[255],"NCT02656069":[256],"NCT03439072.":[258]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W3203034103","counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":5},{"year":2023,"cited_by_count":8},{"year":2022,"cited_by_count":6},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2021-10-11T00:00:00"}
